These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9322679)

  • 1. Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients.
    Nuessler V; Gullis E; Pelka-Fleischer R; del Valle F; Diem H; Beyerlein S; Zwierzina H; Wilmanns W
    Ann Hematol; 1997; 75(1-2):17-26. PubMed ID: 9322679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-glycoprotein expression in patients with acute leukemia-clinical relevance.
    Nüssler V; Pelka-Fleischer R; Zwierzina H; Nerl C; Beckert B; Gieseler F; Diem H; Ledderose G; Gullis E; Sauer H; Wilmanns W
    Leukemia; 1996 Jul; 10 Suppl 3():S23-S31. PubMed ID: 8656697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
    Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
    Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
    Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracycline drugs and MDR expression in human leukemia.
    Pogliani EM; Belotti D; Rivolta GF; Maffè PF; Corneo G
    Cytotechnology; 1996; 19(3):229-35. PubMed ID: 8862011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversal.
    Nüssler V; Pelka-Fleischer R; Zwierzina H; Nerl C; Beckert B; Gullis E; Gieseler F; Bock S; Bartl R; Petrides PE
    Ann Hematol; 1994; 69 Suppl 1():S25-9. PubMed ID: 7914749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
    List AF; Spier CS; Grogan TM; Johnson C; Roe DJ; Greer JP; Wolff SN; Broxterman HJ; Scheffer GL; Scheper RJ; Dalton WS
    Blood; 1996 Mar; 87(6):2464-9. PubMed ID: 8630412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
    Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
    Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study.
    Ivy SP; Olshefski RS; Taylor BJ; Patel KM; Reaman GH
    Blood; 1996 Jul; 88(1):309-18. PubMed ID: 8704189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
    Benderra Z; Faussat AM; Sayada L; Perrot JY; Chaoui D; Marie JP; Legrand O
    Clin Cancer Res; 2004 Dec; 10(23):7896-902. PubMed ID: 15585622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
    Willman CL
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia.
    van der Kolk DM; de Vries EG; Noordhoek L; van den Berg E; van der Pol MA; Müller M; Vellenga E
    Leukemia; 2001 Oct; 15(10):1544-53. PubMed ID: 11587212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
    Ludescher C; Eisterer W; Hilbe W; Gotwald M; Hofmann J; Zabernigg A; Cianfriglia M; Thaler J
    Leukemia; 1995 Feb; 9(2):350-6. PubMed ID: 7869774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
    Advani R; Saba HI; Tallman MS; Rowe JM; Wiernik PH; Ramek J; Dugan K; Lum B; Villena J; Davis E; Paietta E; Litchman M; Sikic BI; Greenberg PL
    Blood; 1999 Feb; 93(3):787-95. PubMed ID: 9920827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression.
    Nüssler V; Gieseler F; Zwierzina H; Gullis E; Pelka-Fleischer R; Diem H; Abenhardt W; Schmitt R; Langenmayer I; Wohlrab A; Kolb HJ; Wilmanns W
    Ann Hematol; 1997 Feb; 74(2):57-64. PubMed ID: 9063374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
    Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
    Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
    Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
    Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
    Sonneveld P; Burnett A; Vossebeld P; Ben-Am M; Rosenkranz G; Pfister C; Verhoef G; Dekker A; Ossenkoppele G; Ferrant C; Yin L; Gratwohl A; Kovacsovics T; Vellenga E; Capdeville R; Löwenberg B
    Hematol J; 2000; 1(6):411-21. PubMed ID: 11920222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia.
    Higashi Y; Turzanski J; Pallis M; Russell NH
    Br J Haematol; 2000 Nov; 111(2):565-9. PubMed ID: 11122104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
    van der Kolk DM; de Vries EG; van Putten WJ; Verdonck LF; Ossenkoppele GJ; Verhoef GE; Vellenga E
    Clin Cancer Res; 2000 Aug; 6(8):3205-14. PubMed ID: 10955805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.